SCHEMBL6479867

SCHEMBL6479867

CCOC(=O)/C=C/c1cccc(-c2ccc3c(c2OCc2ccccc2)C(C)(C)CCC3(C)C)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.42
AKR1B10 O60218 4/20 0.41
AKR1B1 P15121 4/20 0.41
BACE1 P56817 2/20 0.41
KDM4E B2RXH2 3/20 0.41
ALDH1A1 P00352 2/20 0.41
PKM P14618 1/20 0.41
TTR P02766 2/20 0.40
CA12 O43570 3/20 0.39
CA7 P43166 3/20 0.39
CA9 Q16790 3/20 0.39
CA14 Q9ULX7 3/20 0.39
CA4 P22748 2/20 0.39
CA6 P23280 2/20 0.39
CA5A P35218 2/20 0.39
CA5B Q9Y2D0 2/20 0.39
PTGS2 P35354 1/20 0.39
BCHE P06276 1/20 0.38
DPP4 P27487 1/20 0.38
ALOX5 P09917 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6479871 1.00 LMNA (0.42) LMNAAKR1B10AKR1B1BACE1KDM4E
SCHEMBL6478560 0.91 BCHE (0.43) LMNAAKR1B10AKR1B1BACE1KDM4E
SCHEMBL6478564 0.91 BCHE (0.43) LMNAAKR1B10AKR1B1BACE1KDM4E
SCHEMBL6472753 0.90 KDM4E (0.52) LMNABACE1KDM4EALDH1A1PKM
SCHEMBL6472750 0.90 KDM4E (0.52) LMNABACE1KDM4EALDH1A1PKM
SCHEMBL6874284 0.79 RXRA (0.50) AKR1B10AKR1B1BACE1ALDH1A1TTR
SCHEMBL6472627 0.79 CYP26A1 (0.42) KDM4EALDH1A1PKM
SCHEMBL6472625 0.79 CYP26A1 (0.42) KDM4EALDH1A1PKM
SCHEMBL6880803 0.79 RARA (0.50) BACE1TTRCA12CA7CA9
SCHEMBL8418564 0.74 MRGPRX4 (0.56) LMNAAKR1B10AKR1B1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6924388-B2 Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-08-02 US disclosed
US-20040092594-A1 Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2004-05-13 US disclosed
US-6632963-B1 Are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2003-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092594-A1 Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof AHR, TYR, MC1R LMNA 704/4885AKR1B10 540/4885AKR1B1 399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.